MedDataX Logo

Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status

NCT ID: NCT01210248

Last Updated: 2010-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS:

1. GENETIC (FOR CYP450 2C19)
2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY)
3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BLOOD COLLECTION

BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 OLD PATIENTS
* THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK

Exclusion Criteria

* PREGNANCY
* CHRONIC LIVER DISEASES
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assaf Harofeh Medical Center

Zeriffin, Israel, Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ADINA BAR HAIM, PhD

Role: CONTACT

Phone: 08-9779897

Email: [email protected]

VICTORIA PAPIASHVILI, M.Sc

Role: CONTACT

Phone: 0577345973

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ADINA BAR HAIM, PhD

Role: primary

VICTORIA PAPIASHVILI, M.Sc

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NO 51/10

Identifier Type: -

Identifier Source: org_study_id